Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
Rosenbaum Marc Wade reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that Chief Accounting Officer Marc Wade Rosenbaum received a grant of 2,508 Restricted Stock Units (RSUs) of common stock on February 25, 2026. Each RSU represents one share, with 25% vesting on March 1, 2027 and on each following one-year anniversary, subject to continued service. Following this award, his directly held common stock position is 17,522 shares.
Murphy Patrick Michael reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings executive Patrick Michael Murphy, the company’s CBO and CLO, received an equity award covering 7,024 shares of common stock in the form of Restricted Stock Units (RSUs). Each RSU represents a right to receive one share of common stock at vesting.
According to the filing, 25% of the RSUs vest on March 1, 2027, with an additional 25% vesting on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 67,560 shares of common stock directly.
Smith Mervin reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings EVP Strategic Business Ops Mervin Smith received an equity award of 6,689 restricted stock units of common stock. These RSUs were granted on February 25, 2026 at no cash cost. 25% of the units vest on March 1, 2027 and on each one-year anniversary after that, so long as he continues as a service provider. Following this award, he directly holds 26,964 shares of common stock.
iRhythm Holdings, Inc. executive Sean Clinton Freeman, EVP of Strategy & Corporate Development, reported an equity award on Form 4. He acquired 7,525 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per unit, bringing his directly held total to 14,286 shares after the grant. The RSUs vest over four years, with 25% vesting on March 1, 2027 and additional 25% installments on each one-year anniversary, so long as he continues as a service provider through each vesting date.
Shrishrimal Sumi reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, received a grant of 5,518 shares of Common Stock in the form of Restricted Stock Units (RSUs) on February 25, 2026 at a stated price of $0.00 per share. Following this equity award, her directly held common stock position is reported as 44,700 shares. Each RSU represents a right to receive one share of common stock, with 25% of the RSUs scheduled to vest on March 1, 2027 and the remaining RSUs vesting in equal installments on each one-year anniversary thereafter, contingent on her continued service.
Lawrence Brian Lee reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings Chief Technology Officer Lawrence Brian Lee reported receiving an equity award tied to the company’s common stock. He was granted 6,689 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock for no cash payment.
According to the award terms, 25% of the RSUs vest on March 1, 2027 and on each one-year anniversary thereafter, as long as he continues as a service provider through each vesting date. After this grant, Lee directly holds 21,168 shares of common stock, reflecting his increased equity-based stake in the company.
iRhythm Holdings Chief Financial Officer Daniel G. Wilson reported RSU vesting and related share sales. On February 24, 2026, he acquired 9,412 shares of common stock at no cost upon the Compensation & Human Capital Management Committee determining performance RSU conditions were met. On February 25, 2026, he sold 5,188 shares at an average price of $135.4189 to cover tax withholding and remittance obligations from the RSU vesting. After these transactions, he directly held 30,694 shares and indirectly held 100 shares through The Wilson Living Trust, where he serves as trustee.
iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president Mervin Smith reported performance-based equity vesting and related tax sales of company stock. He acquired 9,210 shares of common stock on February 24, 2026 at $0.00 per share from performance RSUs after a board committee determined the performance conditions were met.
On February 25, 2026, he sold 4,041 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to the RSU vesting. After these transactions, he directly owned 20,275 shares of iRhythm common stock.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported equity compensation activity and a related tax sale. On February 24, 2026, she acquired 11,294 shares of common stock at $0.00 per share from performance RSUs granted on February 27, 2023, after the board committee determined performance conditions were met. This increased her direct holdings to 45,399 shares. On February 25, 2026, she sold 6,217 shares of common stock at an average price of $135.4189 per share, leaving 39,182 shares held directly. A footnote states these shares were sold to cover tax withholding and remittance obligations tied to the vesting of the performance RSUs.